Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
Total Valuation
Enliven Therapeutics has a market cap or net worth of $1.66B. The enterprise value is $1.56B.
Market Cap$1.66B
Enterprise Value$1.56B
Share Statistics
Enliven Therapeutics has 59,800,407 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,800,407
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Enliven Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -26.01%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-26.01%
Return on Capital Employed (ROCE)-0.26
Revenue Per Employee0.00
Profits Per Employee-1.67M
Employee Count62
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enliven Therapeutics is ―. Enliven Therapeutics’s PEG ratio is 2.65.
PE Ratio―
PS Ratio0.00
PB Ratio1.90
Price to Fair Value1.90
Price to FCF-12.38
Price to Operating Cash Flow-22.38
PEG Ratio2.65
Income Statement
In the last 12 months, Enliven Therapeutics had revenue of 0.00 and earned -103.69M in profits. Earnings per share was -1.83.
Revenue0.00
Gross Profit-263.00K
Operating Income-119.66M
Pretax Income-103.69M
Net Income-103.69M
EBITDA-119.39M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -70.30M and capital expenditures -158.00K, giving a free cash flow of -70.46M billion.
Operating Cash Flow-70.30M
Free Cash Flow-70.46M
Free Cash Flow per Share-1.18
Dividends & Yields
Enliven Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.42
52-Week Price Change31.99%
50-Day Moving Average26.25
200-Day Moving Average21.68
Relative Strength Index (RSI)48.06
Average Volume (3m)725.00K
Important Dates
Enliven Therapeutics upcoming earnings date is May 20, 2026, Before Open (Confirmed).
Last Earnings DateMar 3, 2026
Next Earnings DateMay 20, 2026
Ex-Dividend Date―
Financial Position
Enliven Therapeutics as a current ratio of 28.66, with Debt / Equity ratio of 0.09%
Current Ratio28.66
Quick Ratio28.66
Debt to Market Cap<0.01
Net Debt to EBITDA0.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Enliven Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Enliven Therapeutics EV to EBITDA ratio is -6.48, with an EV/FCF ratio of -10.99.
EV to Sales0.00
EV to EBITDA-6.48
EV to Free Cash Flow-10.99
EV to Operating Cash Flow-11.01
Balance Sheet
Enliven Therapeutics has $462.62M in cash and marketable securities with $399.00K in debt, giving a net cash position of $462.22M billion.
Cash & Marketable Securities$462.62M
Total Debt$399.00K
Net Cash$462.22M
Net Cash Per Share$7.73
Tangible Book Value Per Share$8.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Enliven Therapeutics is $37.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$37.67
Price Target Upside35.65% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast3.18%